Design of targeted dosage form of ofloxacin

The targeted pro-drug is a classical pro-drug design often representing a non-specific chemical approach to mask undesirable drug properties, such as limited bioavailability, lack of site specificity, and chemical instability. On the other hand, targeted pro-drug design represents a new strategy for...

Full description

Bibliographic Details
Main Authors: E. MANOGRAN, M. ASHRAF ALI, A. AHAMED SIDDIQUI, M. SHAHAR YAR
Format: Article
Language:English
Published: Serbian Chemical Society 2006-12-01
Series:Journal of the Serbian Chemical Society
Subjects:
Online Access:http://www.shd.org.yu/HtDocs/SHD/Vol71/No12/JSCS_V71_No12-03.pdf
id doaj-a5bd5f543aa3435e865d0a0c93d4a466
record_format Article
spelling doaj-a5bd5f543aa3435e865d0a0c93d4a4662020-11-25T00:19:14ZengSerbian Chemical Society Journal of the Serbian Chemical Society0352-51392006-12-01711212691273Design of targeted dosage form of ofloxacinE. MANOGRANM. ASHRAF ALIA. AHAMED SIDDIQUIM. SHAHAR YARThe targeted pro-drug is a classical pro-drug design often representing a non-specific chemical approach to mask undesirable drug properties, such as limited bioavailability, lack of site specificity, and chemical instability. On the other hand, targeted pro-drug design represents a new strategy for directed and efficient drug delivery. Quinolone antibiotics exert their pharmacological effect by inhibiting the cell wall synthesis of the pathogen. However, development of resistance exists, which instigates for a new higher congener to remain in clinical practice. To overcome this phenomenon and also to produce site-specific activity of the cell walls of the pathogen, ofloxacin is conjugated with a hydroxypropyl methacrylamide polymer backbone moiety. The results of in vitro release studies indicate the possibilities for the development of a new drug for site-specific therapy with an improved t1/2 of the drug. This novel pro-drugmay have opened a new vista in antibiotic chemotherapy.http://www.shd.org.yu/HtDocs/SHD/Vol71/No12/JSCS_V71_No12-03.pdfofloxacinhydroxypropyl methacrylamidebioavailabilitypro-drug
collection DOAJ
language English
format Article
sources DOAJ
author E. MANOGRAN
M. ASHRAF ALI
A. AHAMED SIDDIQUI
M. SHAHAR YAR
spellingShingle E. MANOGRAN
M. ASHRAF ALI
A. AHAMED SIDDIQUI
M. SHAHAR YAR
Design of targeted dosage form of ofloxacin
Journal of the Serbian Chemical Society
ofloxacin
hydroxypropyl methacrylamide
bioavailability
pro-drug
author_facet E. MANOGRAN
M. ASHRAF ALI
A. AHAMED SIDDIQUI
M. SHAHAR YAR
author_sort E. MANOGRAN
title Design of targeted dosage form of ofloxacin
title_short Design of targeted dosage form of ofloxacin
title_full Design of targeted dosage form of ofloxacin
title_fullStr Design of targeted dosage form of ofloxacin
title_full_unstemmed Design of targeted dosage form of ofloxacin
title_sort design of targeted dosage form of ofloxacin
publisher Serbian Chemical Society
series Journal of the Serbian Chemical Society
issn 0352-5139
publishDate 2006-12-01
description The targeted pro-drug is a classical pro-drug design often representing a non-specific chemical approach to mask undesirable drug properties, such as limited bioavailability, lack of site specificity, and chemical instability. On the other hand, targeted pro-drug design represents a new strategy for directed and efficient drug delivery. Quinolone antibiotics exert their pharmacological effect by inhibiting the cell wall synthesis of the pathogen. However, development of resistance exists, which instigates for a new higher congener to remain in clinical practice. To overcome this phenomenon and also to produce site-specific activity of the cell walls of the pathogen, ofloxacin is conjugated with a hydroxypropyl methacrylamide polymer backbone moiety. The results of in vitro release studies indicate the possibilities for the development of a new drug for site-specific therapy with an improved t1/2 of the drug. This novel pro-drugmay have opened a new vista in antibiotic chemotherapy.
topic ofloxacin
hydroxypropyl methacrylamide
bioavailability
pro-drug
url http://www.shd.org.yu/HtDocs/SHD/Vol71/No12/JSCS_V71_No12-03.pdf
work_keys_str_mv AT emanogran designoftargeteddosageformofofloxacin
AT mashrafali designoftargeteddosageformofofloxacin
AT aahamedsiddiqui designoftargeteddosageformofofloxacin
AT mshaharyar designoftargeteddosageformofofloxacin
_version_ 1725372552062173184